HER2 is critical in 15–20% of breast cancers, regulating key cell proliferation pathways such as mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT [70]. This evidence concerns the gene ERBB2 and breast carcinoma.